DICYNONE 500 CAPSULE 500mg

Land: Singapur

Sprache: Englisch

Quelle: HSA (Health Sciences Authority)

Wirkstoff:

Etamsylate

Verfügbar ab:

VIFOR PHARMA ASIA PACIFIC PTE. LTD.

ATC-Code:

B02BX01

Dosierung:

500mg

Darreichungsform:

CAPSULE

Verabreichungsweg:

ORAL

Verschreibungstyp:

Prescription Only

Hergestellt von:

OM Pharma S.A.

Berechtigungsdatum:

2012-03-15

Gebrauchsinformation

Dicynone
®
 500
ANTIHAEMORRHAGIC
COMPOSITION
Active principle: Etamsylate
Etamsylate 500 mg. Excipients q.s.f. 1 capsule
PROPERTIES/EFFECTS
Etamsylate is a synthetic antihaemorrhagic and an-
gioprotective drug acting on the first step of hae-
mostasis (endothelium-platelet interaction). By 
improving platelet adhesiveness and restoring cap-
illary resistance, it is able to reduce bleeding time 
and blood losses.
Etamsylate has no vasoconstrictor action; it does 
not influence fibrinolysis nor modify the plasma co-
agulation factors.
PHARMACOKINETICS
When given p.o., etamsylate is slowly absorbed 
from the gastrointestinal tract. After oral administra-
tion of 500 mg etamsylate maximum plasma level, 
i.e. 15 μg/ml, is reached at 4 h, but bioavailability 
is not known. The binding rate to plasma proteins 
is about 95%. Plasma half-life is about 3,7 h. About 
72% of the administered dose are excreted in the 
first 24 h-urine; the molecule is excreted unchanged. 
Etamsylate crosses the placental barrier. Maternal 
and cord blood contain similar concentrations of et-
amsylate. It is not known if etamsylate is excreted in 
the maternal milk.
KINETICS IN PARTICULAR SITUATIONS
It is not known if the pharmacokinetic properties of 
etamsylate are modified in patients suffering from 
renal and/or hepatic function disorders.
INDICATIONS AND USAGE
Dicynone
® 
500 is a synthetic non-hormonal agent, 
used orally to reduce excessive capillary blood loss. 
Dicynone
® 
500 acts principally by maintaining capil-
lary integrity probably by promoting polymerisation 
of mucopolysaccharide in vessel walls.
Following systemic administration of Dicynone
®

500, the mean bleeding time is significantly re-
duced without any effect on cell counts, fibrinolysis, 
plasma protein levels, prothrombin time or clotting 
time.
Dicynone
® 
500 does not have a vasoconstricting ac-
tion nor does it have any effect on hepatic or renal 
function.
Dicynone
® 
500 is used clinicall